Physician profile
Morgan Fox
NPI 1285208074
$4,770.63
in general payments reported to CMS, 2019-2025
19 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what 92% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2022: $723 · 2023: $596 · 2024: $1,308 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,711 · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,710.55 |
| Education | $216.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $555.06 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $501.90 | 2024-2025 | |
| Genzyme Corporation | $499.43 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $480.48 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $446.63 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $415.61 | 2024-2025 | Austedo Xr, Austedo Xr |
| Glaxosmithkline, LLC. | $389.22 | 2022-2025 | Arexvy, Trelegy Ellipta, Menveo |
| Orexo US, INC. | $371.51 | 2022-2025 | Zubsolv |
| Takeda Pharmaceuticals U.S.A., INC. | $267.15 | 2022-2024 | Glassia |
| Otsuka America Pharmaceutical, INC. | $250.94 | 2025 | Rexulti |
| Csl Behring | $125.00 | 2022 | |
| Lundbeck LLC | $115.92 | 2024-2025 | Rexulti |
| Gilead Sciences, INC. | $106.88 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $72.85 | 2024-2025 | Ingrezza |
| Exact Sciences Corporation | $55.60 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $49.45 | 2024-2025 | Mounjaro, Zepbound |
| Braeburn INC. | $28.14 | 2025 | Brixadi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.69 | 2022 | |
| Axsome Therapeutics, INC. | $17.17 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.